Krijn Kristian Dijkstra

Krijn Kristian Dijkstra

Auto-generated profile, based on publicly available information

Krijn Kristian Dijkstra

The Netherlands Cancer Institute, Amsterdam, Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Cell
Verified
Journal Article
Closed access
KDKrijn K. Dijkstra
Krijn K. Dijkstra
CCChiara M. Cattaneo
Chiara M. Cattaneo
FWFleur Weeber
Fleur Weeber
MCMyriam Chalabi
Myriam Chalabi
JHJoris van de Haar
Joris van de Haar
EVE.E. Voest
E.E. Voest

14 January 2019 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
NSNorman Sachs
Norman Sachs
APAngelos Papaspyropoulos
Angelos Papaspyropoulos
DODomenique D Zomer‐Van Ommen
Domenique D Zomer‐Van Ommen
IHInha Heo
Inha Heo
LBLena Böttinger
Lena Böttinger
Hans CleversHans Clevers
Hans Clevers
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

9 October 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SOSalo N. Ooft
Salo N. Ooft
FWFleur Weeber
Fleur Weeber
KDKrijn K. Dijkstra
Krijn K. Dijkstra
CMChelsea McLean
Chelsea McLean
SKSovann Kaing
Sovann Kaing
EVE.E. Voest
E.E. Voest
Tumor organoids from individual patients with metastatic colorectal cancer can help predict response to irinotecan with or without 5-fluorouracil.

1 September 2017 in Cell Chemical Biology
Verified
Journal Article
Closed access
FWFleur Weeber
Fleur Weeber
SOSalo N. Ooft
Salo N. Ooft
KDKrijn K. Dijkstra
Krijn K. Dijkstra
EVE.E. Voest
E.E. Voest

12 October 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
FWFleur Weeber
Fleur Weeber
MWMarc van de Wetering
Marc van de Wetering
MHMarlous Hoogstraat
Marlous Hoogstraat
KDKrijn K. Dijkstra
Krijn K. Dijkstra
OKOscar Krijgsman
Oscar Krijgsman
EVE.E. Voest
E.E. Voest
Tumor organoids are 3D cultures of cancer cells. They can be derived from the tumor of each individual patient, thereby providing an attractive ex vivo assay to tailor treatment. Using patient-derived tumor organoids for this purpose requires that organoids derived from biopsies maintain the genetic diversity of the in vivo tumor. In this study tumor biopsies were obtained from 14 patients with metastatic colorectal cancer (i) to test the feasibility of organoid culture from metastatic biopsy specimens and (ii) to compare the genetic diversity of patient-derived tumor organoids and the original tumor biopsy. Genetic analysis was performed using SOLiD sequencing for 1,977 cancer-relevant genes. Copy number profiles were generated from sequencing data using CopywriteR. Here we demonstrate that organoid cultures can be established from tumor biopsies of patients with metastatic colorectal cancer with a success rate of 71%. Genetic analysis showed that organoids reflect the metastasis from which they were derived. Ninety percent of somatic mutations were shared between organoids and biopsies from the same patient, and the DNA copy number profiles of organoids and the corresponding original tumor show a correlation of 0.89. Most importantly, none of the mutations that were found exclusively in either the tumor or organoid culture are in driver genes or genes amenable for drug targeting. These findings support further exploration of patient-derived organoids as an ex vivo platform to personalize anticancer treatment.

12 April 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
KEKatey S. S. Enfield
Katey S. S. Enfield
ECEmma Colliver
Emma Colliver
CLClaudia S Y. Lee
Claudia S Y. Lee
AMAlastair Magness
Alastair Magness
DMDavid A. Moore
David A. Moore
MAMihaela Angelova
Mihaela Angelova
Understanding the role of the tumor microenvironment (TME) in lung cancer is critical to improving patient outcomes. We identified four histology-independent archetype TMEs in treatment-naïve early-stage lung cancer using imaging mass cytometry in the TRACERx study (n = 81 patients/198 samples/2.3 million cells). In immune-hot adenocarcinomas, spatial niches of T cells and macrophages increased with clonal neoantigen burden, whereas such an increase was observed for niches of plasma and B cells in immune-excluded squamous cell carcinomas (LUSC). Immune-low TMEs were associated with fibroblast barriers to immune infiltration. The fourth archetype, characterized by sparse lymphocytes and high tumor-associated neutrophil (TAN) infiltration, had tumor cells spatially separated from vasculature and exhibited low spatial intratumor heterogeneity. TAN-high LUSC had frequent PIK3CA mutations. TAN-high tumors harbored recently expanded and metastasis-seeding subclones and had a shorter disease-free survival independent of stage. These findings delineate genomic, immune, and physical barriers to immune surveillance and implicate neutrophil-rich TMEs in metastasis. Significance: This study provides novel insights into the spatial organization of the lung cancer TME in the context of tumor immunogenicity, tumor heterogeneity, and cancer evolution. Pairing the tumor evolutionary history with the spatially resolved TME suggests mechanistic hypotheses for tumor progression and metastasis with implications for patient outcome and treatment. This article is featured in Selected Articles from This Issue, p. 897